source
- Atara and Pierre Fabre's T-cell therapy gets new chance for FDA approval after twice rejectedAtara Biotherapeutics and Pierre Fabre Pharmaceuticals have received notice from the U.S. FDA that it will reconsider a previously rejected T-cell therapy. The therapy, which had been turned down…
- Clinicians map next-line EGFR lung cancer treatments using NGS, radiation, chemo, amivantamab and ADCsClinicians treating non‑small cell lung cancer with EGFR mutations must adapt when tumors become resistant to first‑line therapies. The latest guidance highlights the use of next‑generation sequenc…